Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...

The companies have teamed to develop an alternative to TAVR that combines the benefits of a less-invasive procedure with the ...

Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.

Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical ...

Investing.com -- Edwards Lifesciences (NYSE:EW) stock rose 4.5% following the presentation of new data showing long-term benefits and valve performance of its SAPIEN 3 TAVR.

PLYMOUTH MEETING, Pa. (WPVI) -- The TAVR procedure has revolutionized a challenging task in heart care: fixing stiff valves. And it has made the process much easier for patients, getting them back to ...

Saint Alphonsus in Boise earned a three-star TAVR ranking from STS and ACC, placing it among the nation’s top heart programs ...

Transcatheter aortic valve replacement (TAVR) is a procedure that can treat narrowing of the aortic valve in the heart. It involves an expandable replacement valve that helps improve blood flow. A ...

The Global Transcatheter Aortic Valve Replacement (TAVR) Market is set to play a transformative role in cardiovascular care, enabling patients with severe aortic stenosis to receive life-saving ...

Since the adoption of transcatheter aortic-valve replacement (TAVR), questions have been raised about its effect on clinical practice in comparison with the effect of surgical aortic-valve replacement ...

Abbott (NYSE: ABT) reported new study findings supporting the use of its Tendyne transcatheter mitral valve replacement (TMVR ...

A Delaware judge correctly interpreted transcatheter aortic valve-replacement device patents that were asserted against ...